Xu MJ, et al. - This retrospective cohort study was designed to identify patients with pelvic or abdominal recurrence after surgery for stage I/II endometrial carcinoma and describe symptoms at presentation, prognostic factors, and salvage treatment toxicity. Findings showed that curative salvage therapy could result in long-term survival for pelvic or abdominal recurrences. The presence of symptoms was negatively associated with treatment outcome, and imaging could be effective for diagnosis in symptomatic and asymptomatic patients.

Methods

• Researchers included 20 consecutively treated patients with recurrence after treatment for stage I/II endometrial carcinoma followed by their Institution’s Radiation Oncology Department from 1998 to 2015.

Results

• Pelvic or abdominal recurrence was observed at the median time of 18.1 months (range, 4.2 to 59.6 mo).
• Fifty percent of recurrences were observed at extranodal locations.
• Researchers observed two-year progression-free survival (PFS) of 44% and 2-year overall survival (OS) of 82%.
• They noticed wide variation in salvage treatments that included chemotherapy and radiotherapy (RT) (7), surgery and RT (3), and surgery, chemotherapy, and RT (3).
• Univariate analysis of PFS suggested that symptoms at recurrence (P=0.04) and extranodal recurrences (P < 0.01) had statistically significant negative association with PFS.
• Univariate analysis of OS suggested that increasing age at recurrence and presence of symptoms had statistically significant association with negative OS outcomes (P=0.08 and P=0.10, respectively).